Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications

被引:1
|
作者
Cheng, Shizhou [1 ]
Zhang, Shu [1 ]
Huang, Mingyan [1 ]
Liu, Yuxuan [1 ]
Zou, Xunyu [1 ]
Chen, Xiaoming [1 ]
Zhang, Zuhai [1 ]
机构
[1] Yangtze Univ, Dept Ophthalmol, Affiliated Hosp 1, Jingzhou, Peoples R China
关键词
neovascular age-related macular degeneration; vascular endothelial growth factor; treatment; mechanism; clinical application; INTRAVITREAL AFLIBERCEPT INJECTION; RANIBIZUMAB; THERAPY; VEGF; ANGIOGENESIS; OUTCOMES; PHARMACOKINETICS; CLASSIFICATION; DISCOVERY; HISTORY;
D O I
10.3389/fmed.2024.1411278
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neovascular age-related macular degeneration (nARMD) is an important cause of visual impairment and blindness in the elderly, with choroidal neovascularization in the macula as the main pathological feature. The onset of nARMD is closely related to factors including age, oxidative stress, and lipid metabolism. Vascular endothelial growth factor (VEGF) is an important factor contributing to nARMD as well as choroidal neovascularization and retinal leakage formation. At present, anti-VEGF therapy is the only treatment that improves vision and halts disease progression in most patients, making anti-VEGF drugs a landmark development for nARMD treatment. Although intravitreal injection of anti-VEGF drugs has become the first-line treatment for nARMD, this treatment has many shortcomings including repeated injections, poor or no response in some patients, and complications such as retinal fibrosis. As a result, several new anti-VEGF drugs are being developed. This review provides a discussion of these new anti-VEGF drugs for the treatment of nARMD.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration
    Ip, Michael S.
    Scott, Ingrid U.
    Brown, Gary C.
    Brown, Melissa M.
    Ho, Allen C.
    Huang, Suber S.
    Recchia, Franco M.
    OPHTHALMOLOGY, 2008, 115 (10) : 1837 - 1846
  • [32] Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Holekamp, Nancy
    Gentile, Brittany
    Giocanti-Auregan, Audrey
    Garcia-Layana, Alfredo
    Peto, Tunde
    Viola, Francesco
    Kertes, Peter J.
    Mirt, Mirela
    Kotecha, Aachal
    Lambert, Jeremy
    Lewis, Hannah B.
    Chi, Gloria C.
    OPHTHALMIC RESEARCH, 2024, 67 (01) : 311 - 321
  • [33] Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Viola, Francesco
    Chi, Gloria C.
    Holekamp, Nancy M.
    Giocanti-Auregan, Audrey
    Garcia-Layana, Alfredo
    Peto, Tunde
    Kertes, Peter J.
    Mirt, Mirela
    Kotecha, Aachal
    Lambert, Jeremy
    Lewis, Hannah B.
    Gentile, Brittany
    OPHTHALMIC RESEARCH, 2024, 67 (01) : 516 - 527
  • [34] Choroidal Thickness following Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
    So, Charlotte
    Ravage, Zac
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [35] GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Xu, Luna
    Mrejen, Sarah
    Jung, Jesse J.
    Gallego-Pinazo, Roberto
    Thompson, Desmond
    Marsiglia, Marcela
    Freund, K. Bailey
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (02): : 176 - 186
  • [36] Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
    Joel Hanhart
    Rony Wiener
    Hashem Totah
    Evgeny Gelman
    Yishay Weill
    Adi Abulafia
    David Zadok
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 1907 - 1914
  • [37] Combination Therapy for Neovascular Age-related Macular Degeneration Refractory to Anti-Vascular Endothelial Growth Factor Agents
    Tozer, Kevin
    Roller, A. Brock
    Chong, Lawrence P.
    Sadda, SriniVas
    Folk, James C.
    Mahajan, Vinit B.
    Russell, Stephen R.
    Boldt, H. Culver
    Sohn, Elliott H.
    OPHTHALMOLOGY, 2013, 120 (10) : 2029 - 2034
  • [38] Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration
    Okada, Mali
    Wong, Tien Yin
    Mitchell, Paul
    Eldem, Bora
    Talks, S. James
    Aslam, Tariq
    Daien, Vincent
    Rodriguez, Francisco J.
    Gale, Richard
    Barratt, Jane
    Finger, Robert P.
    Loewenstein, Anat
    JAMA OPHTHALMOLOGY, 2021, 139 (07) : 769 - 776
  • [39] Final Impact of Anti-Vascular Endothelial Growth Factor Treatment in Age-related Macular Degeneration
    Yang, Jangmi
    Shin, Sang Jin
    Suh, Jae Kyung
    Cho, Songhee
    Tchoe, Hajin
    Kang, Min Joo
    Jee, Donghyun
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2018, 59 (11): : 1039 - 1048
  • [40] Depression Despite Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration
    Casten, Robin
    Rovner, Barry W.
    Leiby, Benjamin E.
    Tasman, William
    ARCHIVES OF OPHTHALMOLOGY, 2010, 128 (04) : 506 - 508